# Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

> **NCT06696183** · PHASE2 · RECRUITING · sponsor: **Technische Universität Dresden** · enrollment: 60 (estimated)

## Conditions studied

- AML - Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gilteritinib (GILT)
- **DRUG:** Venetoclax (VEN)
- **DRUG:** Azacitidine (AZA)

## Key facts

- **NCT ID:** NCT06696183
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-25
- **Primary completion:** 2029-04
- **Final completion:** 2030-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06696183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06696183, "Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06696183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*